Retinoic acid may increase the risk of bone marrow transplant nephropathy

Pediatr Nephrol. 2005 Apr;20(4):534-8. doi: 10.1007/s00467-004-1775-7. Epub 2005 Feb 18.

Abstract

Bone marrow transplant nephropathy (BMTN) classically presents more than 100 days after transplantation as an acute nephritis with hypertension, azotaemia and anemia that usually results in end stage renal failure (ESRF). The risk of developing BMTN may be greater with the use of more intensive chemotherapy and higher total body and tumor bed irradiation. Cis-retinoic acid (RA) may further increase the risk of developing BMTN. Here, we report the cases of two children who developed typical clinical and biochemical features of BMTN. They were both treated for stage IV neuroblastoma with chemotherapy, bone marrow transplant (BMT) conditioning that included total body irradiation and RA therapy after BMT, although the patient in case 1 had established renal insufficiency prior to the commencement of RA. Renal biopsy of these children showed classical BMTN histology, and the renal manifestations progressed quickly; the patient in case 1 became dialysis dependent by 1 year post-bone marrow transplant. Recently, RA has been added to the post-BMT therapy in children with stage IV neuroblastoma. The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental. Although RA has been shown to confer a significant survival advantage in this disease, animal studies and a previous case report have suggested it could increase the toxic effects of chemotherapy and renal irradiation. It is likely that RA contributed to the deterioration in renal function in these patients.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Transplantation / adverse effects*
  • Child, Preschool
  • Female
  • Humans
  • Kidney / pathology
  • Kidney Diseases / etiology*
  • Kidney Diseases / pathology
  • Male
  • Neoplasm Staging
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / pathology
  • Neuroblastoma / surgery*
  • Postoperative Care
  • Stereoisomerism
  • Tretinoin / administration & dosage
  • Tretinoin / adverse effects*
  • Tretinoin / therapeutic use

Substances

  • Antineoplastic Agents
  • Tretinoin